Check-Cap to merge with MBody AI in embodied AI workforce push
Investing.com - Piper Sandler raised its price target on GeneDx (NASDAQ:WGS) to $140 from $120 on Thursday, while maintaining an Overweight rating on the stock. According to InvestingPro data, the stock has delivered an impressive 249% return over the past year, with analyst targets ranging from $95 to $163.
The research firm cited GeneDx’s unique data asset, demonstrated execution, and compelling growth prospects as key factors supporting its positive outlook on the company. This optimism appears well-founded, with the company achieving 48.7% revenue growth in the last twelve months.
Piper Sandler highlighted the company’s ability to build markets within the rare disease testing landscape and its strategic expansion into high-potential areas like the NICU and general pediatrics, creating what it views as a multi-year growth story.
Recent progress on reimbursement and the opportunity to leverage Fabric Genomics for international expansion were also noted as factors that further solidify the company’s potential long-term value.
While acknowledging execution risks involved in scaling new markets and integrating acquisitions, Piper Sandler expressed confidence in GeneDx’s leadership, differentiated data position, and proactive strategy.
In other recent news, GeneDx Holdings Corp reported impressive financial results for the second quarter of 2025, significantly surpassing earnings and revenue forecasts. The company achieved earnings per share of $0.50, which was notably higher than the anticipated $0.12, representing a surprise of over 316%. Revenue for the quarter reached $102.7 million, exceeding the forecasted $85.45 million by 20.19%. Following these results, BTIG raised its price target for GeneDx to $125 from $100, maintaining a Buy rating due to what it described as a "strong bounce-back" in the quarter. Piper Sandler also maintained its Overweight rating on GeneDx, citing multiyear growth potential and raising its revenue projections after the company beat expectations. These developments reflect positive analyst sentiment and strong performance for GeneDx in recent times.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.